Sequenom's Q4 Revenues Drop 11 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Monday that its fourth-quarter revenues dropped 11 percent due to lower sales for its MassArray products and services and an increase in spending.

The San Diego-based molecular diagnostics firm generated total revenues of $10.8 million for the three months ended Dec. 31, compared to $12.2 million for the fourth quarter of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.